Applied DNA posts FY2024 revenue of $3.4M, net loss $7.1M; announces restructuring and leadership changes

BNB PLUS CORP.

Q4 revenue $813K (up vs $780K YoY); FY revenue $3.4M vs $13.4M; net loss Q4 $3.3M ($0.32/sh), FY $7.1M ($1.82/sh).
Pursuing divestiture of CertainT platform; targeting 15% opex reduction vs FY2024, expected by Q2 FY2025.
Judith Murrah promoted to President (salary increased to $400K); Clay Shorrock named President of LineaRx subsidiary.
GMP manufacturing facility buildout to complete by Jan 9, 2025; annual revenue capacity $4M-$16M depending on product mix.
Raised $5.8M net in registered direct offering on Oct 31, 2024; cash ~$10.1M as of Nov 3, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.